Tampa, FLNCT05504707Now EnrollingIRB Ready

Triple Negative Breast Cancer Clinical Trial in Tampa, FL

Access cutting-edge triple negative breast cancer treatment through this phase 1 clinical trial at a research site in Tampa. Study-provided care at no cost to qualified participants.

Sponsored by H. Lee Moffitt Cancer Center and Research Institute

Quick Self-Assessment

See if you qualify for this Tampa location

Preparing your pre-screening questions…

Expert Care in Tampa

Access triple negative breast cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related triple negative breast cancer treatment provided free

Apply for This Tampa Location

Check if you qualify for this triple negative breast cancer clinical trial in Tampa, FL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Tampa

    Convenient for FL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Tampa site if eligible
  4. 4Begin participation

About This Triple Negative Breast Cancer Study in Tampa

The purpose of the study is to find out if an investigational vaccine called Dendritic Cell (DC) vaccine given together with standard of care chemotherapy drugs can help people with Triple Negative and HR low positive breast cancer.

Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Who Can Participate

Inclusion Criteria

A diagnosis of HER2-negative breast cancer.
Diagnosis of HR negative or HR low positive tumor.
Clinical stage T1c, nodal stage N1-N2 or stage T2-4, nodal stage N0-N2 breast cancer.
Participant must be medically and surgically appropriate to undergo neoadjuvant chemotherapy regimen followed by standard of care local therapy as determined by their treating physician.
Age ≥18 years.
ECOG performance status 0 or 1.
Patients must have normal organ and marrow function, as defined below, within 14 days of registration:
\*Absolute neutrophil count (ANC) ≥ 1500/μL
\*Platelets ≥ 75 000/μL
\*Total bilirubin ≤ 1.5 x institutional ULN, except patients with Gilbert's syndrome in whom total bilirubin must be \< 3.0 mg/dL
\*AST/ALT ≤ 3 x institutional ULN
\*Creatinine ≤ 1.5 x institutional ULN
Left ventricular ejection fraction above institutional lower limit of normal (by echocardiogram or MUGA scan).
Female patients of childbearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at screening. Acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal. Effective methods of contraception must be used throughout the study and for 5 months following the last dose. To show that women do not have childbearing potential, postmenopausal women must be amenorrheic for at least 12 months naturally (and not because of/following chemotherapy) or patients must be surgically sterile.
Ability to understand and the willingness to sign a written informed consent agreement prior to study registration.

Exclusion Criteria

Patients who received prior anthracycline-based chemotherapy for the treatment of any cancer.
Patients with inflammatory breast cancer.
Patients must not be receiving any other investigational agents or active antineoplastic therapies.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune-suppressive treatment, including chronic prolonged systemic corticosteroid use (defined as corticosteroid use lasting one month or more).
Female patients who are pregnant or nursing.
No other prior malignancy is allowed, except for the following: a. adequately treated basal-cell or squamous-cell skin cancer, b. in situ cervical cancer, c. or any other cancer from which the patient has been disease free for at least 3 years.
History of testing positive for human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS).
History of positive test for Hepatitis B or Hepatitis C virus indicating acute or chronic infection.
Patients who have received a live attenuated vaccine ≤ 30 days prior to registration.
Unable to comply with the treatment schedule and study procedures for any reason.
Previously treated with breast cancer-directed vaccine therapies in prior 3 months.
Previously treated with any form HER2- or HER3-primed DC1 therapy.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Tampa?

Yes, this clinical trial (NCT05504707) has an active research site in Tampa, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Triple Negative Breast Cancer Treatment Options in Tampa, FL

If you're searching for triple negative breast cancer treatment options in Tampa, FL, this clinical trial (NCT05504707) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Tampa research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced triple negative breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all triple negative breast cancer clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Tampa, FL

See all breast cancer clinical trials recruiting in Tampa — not just this study.

Browse Breast Cancer Trials in Tampa →

Browse More Trials by Condition

Breast Cancer TrialsTriple Negative Breast Cancer TrialsAnkylosing Spondylitis TrialsGeographic Atrophy TrialsAll Conditions →

Ready to Join in Tampa?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Tampa, FL